- Case Report
Ibrutinib-Associated Liver Injury in a Patient with Chronic Lymphocytic Leukemia: Clinical Course and Therapeutic Approach
- Antonio Frolli,
- Guido Parvis,
- Martina Bullo,
- Selene Grano,
- Giovanni Fornari,
- Valentina Bonuomo,
- Daniela Cilloni and
- Carmen Fava
Background: Ibrutinib, a Bruton’s tyrosine kinase inhibitor (BTKi), has revolutionized the treatment of Chronic Lymphocytic Leukemia (CLL), yet hepatotoxicity remains a rare and poorly characterized adverse event. Case Presentation: We report t...

